Great service
Great service as always.
Abu Siddique
Wegovy (Semaglutide)
Weekly injection, up to ~15% at the standard dose, and up to ~21% at the new higher 7.2mg dose, in clinical trials
Start consultation From £16.25 per week
GPhC registered
Pharmacist reviewed
Cold chain delivery
15%
average body weight loss at 2.4mg dose (STEP-1, 68 weeks)
20%
reduction in major cardiovascular events (SELECT trial, NEJM 2023)
68 wks
duration of the landmark STEP-1 clinical trial
1
the only weight loss medication with a licensed cardiovascular indication
Weight loss estimator
See how much you could lose with Wegovy
Enter your starting weight. Based on STEP-1 clinical trial averages, individual results vary.
kg
40 kg200 kg
What this is based on
Based on average 15% body weight loss at 2.4mg in STEP-1 (Wilding JPH et al., NEJM 2021). Results depend on dose reached, adherence, and individual response.
IN ONE YEAR YOU COULD LOSE
13.5 kg
and reach approximately 76.5 kg
percentage lost
15%
target weight
76.5 kg
Based on average 15% body weight loss at 2.4mg in STEP-1 (Wilding JPH et al., NEJM 2021). Results depend on dose reached, adherence, and individual response.
Check your eligibility. Start free consultationGLP-1 science
How Wegovy signals fullness to your brain
Wegovy (semaglutide 2.4mg) mimics GLP-1, a hormone naturally released after eating. By activating GLP-1 receptors in the brain's hypothalamus it reduces hunger signals and increases satiety. It also slows gastric emptying. Crucially, in 2023 Wegovy became the first weight loss medication proven to reduce the risk of serious cardiovascular events.
0%
Average weight loss STEP-1 (68 weeks, NEJM 2021)
0%
Reduction in major cardiovascular events (SELECT trial, NEJM 2023)
0%
of STEP-1 participants lost at least 10% of body weight
Clinical evidence
The STEP trials and the SELECT cardiovascular landmark
STEP-1 (NEJM 2021) showed 14.9% average weight loss over 68 weeks. The 2023 SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events, heart attack, stroke, cardiovascular death, making Wegovy the only weight loss medication with a proven cardiovascular benefit, licensed by the MHRA for this indication.
Wilding JPH et al. NEJM 2021; Lincoff AM et al. NEJM 2023; NICE TA875
What's included
Everything you need, delivered
Your medication
Prescribed Wegovy pen at your approved dose
Needles
All injection needles included
Antiseptic wipes
For hygienic administration at every injection
Cold chain delivery
Insulated pouches and ice gel packs, Royal Mail 48hr, £3.99
How it works
Why Wegovy is uniquely effective
The only weight loss injection with a proven cardiovascular benefit. Wegovy reduces appetite, slows digestion, and has demonstrated a 20% reduction in serious cardiovascular events in the landmark SELECT trial.
Start your consultationAppetite suppression
Wegovy activates GLP-1 receptors in the brain's hypothalamus, reducing hunger signals and helping you feel satisfied with smaller portions.
Cardiovascular protection
The SELECT trial showed Wegovy reduced the risk of heart attack, stroke, and cardiovascular death by 20%, the only weight loss medication with this licensed indication.
Slower gastric emptying
Food moves more slowly from the stomach, prolonging the feeling of fullness and reducing the urge to eat between meals.
Titration
Your dose journey
Starter doses build tolerability. Weight loss effect builds from 1mg onwards.
You start here0.25mg
·0.5mg
·1mg
·1.7mg
Standard maintenance2.4mg
Higher dose, obesity only7.2mg
A higher 7.2mg dose is available for eligible patients with obesity (BMI 30+) who need additional weight loss.
Eligibility
Is Wegovy right for you?
Treatment may be suitable if your BMI is 30 or above, or 27 or above alongside a weight-related health condition. Our pharmacist will assess your full eligibility during the consultation.
May be suitable
- BMI 30 or above
- BMI 27 to 29 with a weight-related condition
- Adults aged 18 and over
- UK residents
Not suitable if you have
- Personal or family history of medullary thyroid carcinoma or MEN 2
- History of pancreatitis
- Known allergy to semaglutide
- Are pregnant, breastfeeding, or planning pregnancy
Unlike Mounjaro, Wegovy can be used in patients with type 2 diabetes.
Clinical evidence
Clinically proven outcomes
STEP-1 · New England Journal of Medicine · 2021 · SELECT · NEJM · 2023
"Wegovy is the first weight loss medication proven to also protect the heart. For eligible patients, it represents a meaningful advance in how we approach weight management."
Jimah Alsaai MPharm
Superintendent Pharmacist · GPhC 2232652
WEIGHT LOSS OVER TIME
Wegovy vs diet and exercise alone
Chart illustrative, based on STEP-1 trial trajectory. Diet & Exercise arm represents placebo + lifestyle comparator group.
HEADLINE RESULTS
15%
average body weight loss at 2.4mg over 68 weeks
84%
of participants lost at least 5% of body weight
20%
reduction in major adverse cardiovascular events (SELECT trial)
Wilding JPH et al. N Engl J Med 2021;384:989-1002. STEP-1. Lincoff AM et al. N Engl J Med 2023. SELECT trial.
Start your consultationNew in 2026
A higher dose is now available
In 2026 the MHRA approved a higher 7.2mg maintenance dose of Wegovy for adults with obesity. In the STEP UP trial it produced up to around 21% average weight loss over 72 weeks (about 18.7% on a treatment-policy basis), compared with about 15% at the standard 2.4mg dose. It's reached only after titrating to 2.4mg first, and only where your prescriber judges it appropriate.
Read our full guide to Wegovy 7.2mgPricing
Wegovy pricing
New patient
0.25mg
£64.99
£84.99
WELCOME20Per 4-week pen + £3.99 delivery
Start assessmentNew patient
0.5mg
£89.99
£109.99
WELCOME20Per 4-week pen + £3.99 delivery
Start assessmentNew patient
1mg
£109.99
£129.99
WELCOME20Per 4-week pen + £3.99 delivery
Start assessmentNew patient
1.7mg
£149.99
£169.99
WELCOME20Per 4-week pen + £3.99 delivery
Start assessmentNew patient
2.4mg
£179.99
£199.99
WELCOME20Per 4-week pen + £3.99 delivery
Start assessmentNew patients save £20 on their first order with code WELCOME20, applied automatically at checkout.
Select your treatment
Dose0.25mg
Price
£64.99£84.99
Delivery£3.99. Royal Mail 48hr tracked
New patients save £20 on their first order with code WELCOME20, applied automatically at checkout.
Side effects
What to expect
Like all medicines, Wegovy can cause side effects. Most are mild and improve as your body adjusts to the medication. The side effect profile is similar to Mounjaro though some studies suggest slightly lower incidence of nausea with semaglutide compared to tirzepatide at equivalent weight loss.
Very common (more than 1 in 10)
Nausea · Diarrhoea · Vomiting · Constipation · Decreased appetite
Common (up to 1 in 10)
Indigestion · Abdominal pain · Injection site reactions · Fatigue · Dizziness
Managing them
Starting at the lowest dose and increasing gradually significantly reduces the severity of side effects. Eating smaller meals and staying hydrated helps.
Pharmacist support
Want to speak to our pharmacist before starting?
Our superintendent pharmacist reviews every consultation personally. If you have questions about eligibility, dosing, or side effects before you begin, you can request a callback during your consultation, or start now and our team will be in touch.
Jimah Alsaai MPharm
GPhC 2232652 · Superintendent Pharmacist
What our patients say
Wegovy UK price comparison
Solira's Wegovy pricing vs other UK providers
Full retail prices per dose, no discount. Solira's WELCOME20 first-month price shown in green. Updated August 2026.
| Dose | Solira | Voy | Numan | Juniper | MedExpress | Boots | Superdrug |
|---|---|---|---|---|---|---|---|
| 0.25mgStarting dose | £84.99 £64.99 1st month w/ WELCOME20 Lowest here | ~£129 | £129 | ~£169 | ~£139 | ~£149 | ~£129 |
| 0.5mg | £109.99 £89.99 1st month w/ WELCOME20 Lowest here | ~£139 | ~£149 | ~£189 | ~£149 | ~£169 | ~£139 |
| 1mg | £129.99 £109.99 1st month w/ WELCOME20 Lowest here | ~£149 | ~£169 | ~£209 | ~£169 | ~£189 | ~£169 |
| 1.7mg | £169.99 £149.99 1st month w/ WELCOME20 Lowest here | ~£199 | ~£219 | ~£249 | ~£219 | ~£229 | ~£189 |
| 2.4mg | £199.99 £179.99 1st month w/ WELCOME20 Lowest here | ~£229 | ~£249 | ~£289 | ~£239 | ~£249 | £205 |
Notes: all prices in GBP for a 4-week supply. Solira's WELCOME20 first-month discount applies to new patients only. This comparison covers the named providers shown and is not a claim to be the lowest price in the UK market. "~" = price extrapolated from published competitor announcements and comparison sites. A blank cell means the dose is not currently offered by that provider.
Updated August 2026
FAQ
Common questions
Both are weekly injections. Mounjaro (tirzepatide) activates GLP-1 and GIP receptors and demonstrates greater average weight loss (22.5% vs 15%). Wegovy is the only weight loss medication proven to reduce cardiovascular risk. Your prescriber will advise which is more appropriate for you.
They contain the same ingredient (semaglutide) at different doses. Ozempic (0.5mg to 2mg) is licensed for type 2 diabetes. Wegovy (2.4mg) is licensed specifically for weight management. They are not interchangeable.
Wegovy is available on the NHS through specialist weight management services in limited circumstances. Private services like Solira allow eligible patients to access it without an NHS referral or waiting list.
If within 5 days of your usual day, take it as soon as possible. If more than 5 days have passed, skip and resume your normal schedule the following week. Never take two doses in one week.
Previous prescription weight loss medications (such as orlistat) worked by blocking fat absorption and produced modest average weight loss of 3% to 5%. Wegovy works on the brain and gut to fundamentally reduce appetite, producing average weight loss of 15%, with over half of patients losing more than 15%.
Yes. The MHRA approved the 7.2mg dose in January 2026 and a single-dose 7.2mg pen in April 2026. It's available privately for eligible adults with obesity (BMI 30+). It is not currently on the NHS at this dose. You reach it by titrating to 2.4mg first.
In the STEP UP trial, the 7.2mg dose produced up to around 21% average weight loss over 72 weeks in people who reached and maintained the dose (about 18.7% on a treatment-policy basis), versus about 15% on the standard 2.4mg dose. Around 1 in 3 lost 25% or more. Individual results vary with the dose reached and adherence.
Wegovy is priced by dose, starting from our lowest starter dose and rising as you titrate up, plus £3.99 delivery. New patients get £20 off their first order with code WELCOME20. There's no separate prescription or consultation fee, a pharmacist review is included.
Most people notice reduced appetite within the first week or two, but meaningful weight loss builds over months as the dose increases. In the STEP-1 trial the average was around 15% of body weight over 68 weeks. The early weeks are about tolerability; the weight-loss effect strengthens from the 1mg dose onward.
Yes. Solira is a GPhC-registered pharmacy, so an eligible patient can complete an online consultation reviewed by our pharmacist, no GP appointment or referral needed. You'll need to share an accurate medical history so we can check it's safe for you.